FDA lets new Pfizer safety data onto Chantix label; Valeant offers 'olive branch' to Allergan;

@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce

> The FDA updated labeling on Pfizer's ($PFE) Chantix to include studies that found little or no evidence of psychiatric issues in patients using it to stop smoking; the company plans to ask FDA to remove the "black box" warning now on the drug. Report

> Valeant Pharmaceuticals ($VRX) offered an "olive branch" to deal target Allergan ($AGN) via letter this week, and now says it's set to beat analyst estimates for the third quarter, answering critics of its business model. Report

> Analysts figure AbbVie ($ABBV) and Shire's ($SHPG) proposed merger will go through despite new U.S. rules on tax inversions. Report

> Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) are donating $1 million to not-for-profit groups focused on cardiovascular education; the two are partners on a blood clot-fighter, Eliquis. Report

> The U.K.'s cost-effectiveness watchdogs are eyeing a "no" vote for biologic treatments for ulcerative colitis. Report

Medical Device News

@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2

@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce

> Little is known about the Sunshine Act site ahead of launch, AdvaMed says. Article

> FDA to weigh in on cybersecurity concerns. Report

Biotech News

@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech

@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce

@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce

> Waksal's back: Once-jailed biotech chief plots an IPO for his latest play. News

> Novartis-partnered Eureka rounds up $21M round for immuno-oncology drug research. Story

> Gilead heads to FDA after wrapping a PhIII HIV combo drug program. Item

> Bristol-Myers plots a 2,500-worker campus in New Jersey. Article

Drug Delivery News

> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item

> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report

> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story

> Titan Pharma trial of implant for addicts on track. Article

> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More

Diagnostics News

> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News

> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report

> Sequenom keeps prenatal Dx competition running with new positive data. Article

> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story

> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More

Pharma Marketing News

> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report

> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More

> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item

> Can copay coupons be kickbacks? HHS says yes. More

> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article

And Finally... A BMJ study found evidence linking the anxiety drugs benzodiazepines to Alzheimer's disease. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.